The bronchodilator effect of intravenous glucagon in asthma exacerbation: A randomized, controlled trial

Wilber, Scott T.; Wilson, James E.; Blanda, Michelle; Gerson, Lowell W.; Meerbaum, Sharon O.; Janas, George

doi:10.1067/mem.2000.110823

Cited by 8 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, when glucagon was given locally in the airways by nebulization, similar to what we performed, in asthmatic patients, no adverse effects was observed 10,46 . In addition, the major shortcoming of the use of glucagon for asthma treatment is that some authors showed that glucagon alone is ineffective for the management of asthma exacerbations 47 , despite its ability to induce bronchodilation, and that several authors found that glucagon was effective for treatment of asthmatic patients, including in the chronic phase of the disease 10,11,45,46,48 .…”

Section: Discussionmentioning

confidence: 99%

Glucagon reduces airway hyperreactivity, inflammation, and remodeling induced by ovalbumin

Insuela

Azevedo

Coutinho

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Glucagon has been shown to be beneficial as a treatment for bronchospasm in asthmatics. Here, we investigate if glucagon would prevent airway hyperreactivity (AHR), lung inflammation, and remodeling in a murine model of asthma. Glucagon (10 and 100 µg/Kg, i.n.) significantly prevented AHR and eosinophilia in BAL and peribronchiolar region induced by ovalbumin (OVA) challenge, while only the dose of 100 µg/Kg of glucagon inhibited subepithelial fibrosis and T lymphocytes accumulation in BAL and lung. The inhibitory action of glucagon occurred in parallel with reduction of OVA-induced generation of IL-4, IL-5, IL-13, TNF-α, eotaxin-1/CCL11, and eotaxin-2/CCL24 but not MDC/CCL22 and TARC/CCL17. The inhibitory effect of glucagon (100 µg/Kg, i.n.) on OVA-induced AHR and collagen deposition was reversed by pre-treatment with indomethacin (10 mg/Kg, i.p.). Glucagon increased intracellular cAMP levels and inhibits anti-CD3 plus anti-CD28-induced proliferation and production of IL-2, IL-4, IL-10, and TNF- α from TCD4 + cells in vitro . These findings suggest that glucagon reduces crucial features of asthma, including AHR, lung inflammation, and remodeling, in a mechanism probably associated with inhibition of eosinophils accumulation and TCD4 + cell proliferation and function. Glucagon should be further investigated as an option for asthma therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Glucagon reduces airway hyperreactivity, inflammation, and remodeling induced by ovalbumin

Insuela

Azevedo

Coutinho

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Systemic corticosteroids and high-dose ICS are known to increase the risk of preeclampsia, low birth weight, and preterm delivery [ 33 , 34 ]. Although several studies and guidelines have emphasized that an adequate dose of ICS and SABA did not affect pregnancy outcomes [ 6 , 35 ], pregnant women have been reluctant to take steroids during pregnancy due to safety concerns. Our findings also support previous results that South Korean asthmatic pregnant women preferred ICS-based inhalers over oral asthma medications regardless of the severity of their asthma and the level of asthma medications before pregnancy [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

“…The prevalence of asthma during pregnancy is known to be 3%–12% [ 2 , 3 ], and the rate of women requiring medical intervention due to exacerbation during pregnancy is about 20% [ 4 ]. It is well known that the maintenance of asthma therapy during pregnancy outweighs the risk to the fetus [ 5 , 6 ]. Poorly controlled asthma can have a negative effect on pregnant women and fetuses.…”

Section: Introductionmentioning

confidence: 99%

Effect of Pregnancy on Quantitative Medication Use and Relation to Exacerbations in Asthma

Koo

Kim

Park

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Background The quantification of asthma medication reduction and its relation to an aggravation of asthma during pregnancy at an individual level are unclear. Methods We conducted a nationwide retrospective cohort study of asthmatic pregnant women in South Korea. All of the asthma medications were ranked from 1 to 4 according to the guideline-based stepwise approach. We assessed the daily sums of the ranks of the asthma medications and their association with exacerbations during three phases based on the individual's delivery date: before, during, and after pregnancy. Results The study cohort included 115,169 asthmatic pregnant women who gave birth between 2011 and 2013. The subjects were clustered into four groups according to the daily rank sums of their asthma medication. Asthma medications were rapidly reduced at the beginning of the pregnancy and then slowly increased after delivery. Exacerbations were more frequent in the group with higher rank-sum values than in the group with lower values. Overall exacerbations were reduced during pregnancy compared to before or after delivery. Conclusions Asthmatic pregnant women tended to reduce their asthma medication use during pregnancy. This led to a greater number of exacerbations in a small part of the study population.

show abstract

“…The article is licensed by CC BY-NC 4.0 International Licensee https://creativecommons.org/licenses/by-nc/4.0/ ние [54,55], а при внутривенном введении глюкагона пациентам, поступившим в стационар с острой брон хообструкцией, клинически значимой немедленной бронходилатации по сравнению с плацебо не показа но [56]. В свою очередь, уровень глюкагона повыша ется при ожирении, а его концентрация варьируется в широком диапазоне в зависимости от характера по требляемой пищи [57].…”

unclassified

Influence of adipocytokines on the bronchopulmonary system in abdominal obesity

Khudiakova,

Ragino

2023

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

Pathogenesis of chronic lung diseases is assumed to involve systemic inflammation factors, as well as hormone-like substances adipokines produced by adipose tissue, which is an independent endocrine organ. Adipokines cause systemic inflammation under the influence of hypoxemia due to obesity and associated respiratory disorders such as obstructive sleep apnea syndrome, chronic obstructive pulmonary disease, hypoventilation syndrome, etc. However, the influence of specific adipocytes on the development and course of bronchopulmonary diseases remains unclear.Purpose of this review was to evaluate the contribution of some adipocytokines to the development of bronchopulmonary conditions against abdominal obesity. We collected data on adiponectin, adipsin, lipocalin-2, interleukin 6, insulin, glucagon, leptin, monocyte-chemoattractant protein type 1, tumor necrosis factor-α, amylin, glucose-dependent insulinotropic polypeptide, ghrelin, and pancreatic polypeptide in patients with abdominal obesity and bronchopulmonary disorders.Conclusion. The presented data confirm that hormone-like substances produced by adipose tissue make a significant contribution to the severity of respiratory disorders.

show abstract

The bronchodilator effect of intravenous glucagon in asthma exacerbation: A randomized, controlled trial

Cited by 8 publications

References 7 publications

Glucagon reduces airway hyperreactivity, inflammation, and remodeling induced by ovalbumin

Glucagon reduces airway hyperreactivity, inflammation, and remodeling induced by ovalbumin

Effect of Pregnancy on Quantitative Medication Use and Relation to Exacerbations in Asthma

Influence of adipocytokines on the bronchopulmonary system in abdominal obesity

Contact Info

Product

Resources

About